NICE backs MabThera for NHL maintenance

The U.K.'s NICE issued a preliminary appraisal recommending the use of MabThera rituximab from Roche (SIX:ROG; OTCQX:RHHBY) as a first-line maintenance treatment of advanced follicular non-Hodgkin's l...